In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

Moderna could have many products on the market and in a variety of areas. Among these, we may find a cytomegalovirus (CMV) vaccine, a personalized cancer vaccine, and a norovirus vaccine.

and norovirus – respectively in and close to phase 3 testing – along with two therapies for rare diseases methylmalonic acidaemia (MMA) and propionic acidaemia (PA) in phase 1/2 and Moderna's ...

A norovirus warning has been issued by the NHS across an area of Scotland, and people have been warned not to visit hospitals if they are experiencing any symptoms of the nasty vomiting bug.

This review summarizes recent developments in norovirus research that are relevant to the prevention and management of norovirus gastroenteritis in immunocompromised patients. Noroviruses are ...

NHS Borders has urged people not to visit loved ones in hospital amid an increase in the number of patients with norovirus. Norovirus is a stomach bug that causes vomiting and diarrhoeaCredit ...

Norovirus is a highly contagious virus that leads to vomiting and diarrhoea Visitor restrictions have been implemented at Naas General Hospital to stop the spread of norovirus. Photo: Google Maps ...

Valued at a market cap of $9.6 billion, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that focuses on developing messenger RNA (mRNA) medicines and vaccines.